Ar­cutis scores FDA ap­proval for new foam treat­ment for com­mon skin con­di­tion

Cal­i­for­nia-based Ar­cutis Bio­ther­a­peu­tics on Fri­day won FDA ap­proval for a new foam-based skin treat­ment for se­b­or­rhe­ic der­mati­tis in in­di­vid­u­als 9 years of age and old­er.

The new top­i­cal foam, known as Zo­ryve (rof­lu­mi­last), is a phos­pho­di­esterase-4 in­hibitor and will be avail­able by the end of Jan­u­ary 2024, the com­pa­ny said. Ar­cutis said the foam will be priced the same as its ap­proved cream for­mu­la­tion, which has a price of $858 a tube. The cream ver­sion of Zo­ryve first won ap­proval in 2022 for the treat­ment of plaque pso­ri­a­sis in pa­tients 12 years of age or old­er. Rof­lu­mi­last first won FDA ap­proval as an oral drug in 2011 for As­traZeneca un­der the brand name Dalire­sp, and to re­duce the risk of COPD flare-ups.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER